Literature DB >> 31902355

Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease.

Hulya Akıncıoğlu1, İlhami Gülçin2.   

Abstract

Alzheimer's disease (AD) is one of the cognitive or memory-related impairments occurring with advancing age. Since its exact mechanism is not known, the full therapy has still not been found. Acetylcholinesterase (AChE) has been reported to be a viable therapeutic target for the treatment of AD and other dementias. To this end, acetylcholinesterase inhibitors (AChEIs) are commonly used. AChE is a member of the hydrolase enzyme family. A hydrolase is an enzyme that catalyzes the hydrolysis of a chemical bond. AChE is useful for the development of novel and mechanism-based inhibitors. It has a role in the breakdown of acetylcholine (ACh) neurotransmitters, such as acetylcholinemediated neurotransmission. AChEIs are the most effective approaches to treat AD. AChE hydrolyzes ACh to acetate and choline, as an important neurotransmitter substance. Recently, Gülçin and his group explored new AChEIs. The most suggested mechanism for AD is the deficiency of ACh, which is an important neurotransmitter. In this regard, AChEIs are commonly used for the symptomatic treatment of AD. They act in different ways, such as by inhibiting AChE, protecting cells from free radical toxicity and β-amyloid-induced injury or inhibiting the release of cytokines from microglia and monocytes. This review focuses on the role of AChEIs in AD using commonly available drugs. Also, the aim of this review is to research and discuss the role of AChEIs in AD using commonly available drugs. Therefore, in our review, related topics like AD and AChEIs are highlighted. Also, the latest work related to AChEIs is compiled. In recent research studies, novel natural and synthetic AChEIs, used for AD, are quite noteworthy. These studies can be very promising in detecting potent drugs against AD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Acetylcholinesterase; Alzheimer’s disease; Cholinesterases (ChEs); enzyme; inhibitor; postsynaptic receptor.

Mesh:

Substances:

Year:  2020        PMID: 31902355     DOI: 10.2174/1389557520666200103100521

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  16 in total

Review 1.  Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies.

Authors:  Tao Song; Xiaopeng Song; Chenyawen Zhu; Regan Patrick; Miranda Skurla; Isabella Santangelo; Morgan Green; David Harper; Boyu Ren; Brent P Forester; Dost Öngür; Fei Du
Journal:  Ageing Res Rev       Date:  2021-10-29       Impact factor: 10.895

2.  Hydroxybenzoic Acids as Acetylcholinesterase Inhibitors: Calorimetric and Docking Simulation Studies.

Authors:  Grażyna Budryn; Iwona Majak; Joanna Grzelczyk; Dominik Szwajgier; Alejandro Rodríguez-Martínez; Horacio Pérez-Sánchez
Journal:  Nutrients       Date:  2022-06-15       Impact factor: 6.706

Review 3.  Curcumin in Health and Diseases: Alzheimer's Disease and Curcumin Analogues, Derivatives, and Hybrids.

Authors:  Eirini Chainoglou; Dimitra Hadjipavlou-Litina
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

Review 4.  Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases.

Authors:  Mootaz M Salman; Zaid Al-Obaidi; Philip Kitchen; Andrea Loreto; Roslyn M Bill; Richard Wade-Martins
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

5.  Acetylcholinesterase and butyrylcholinesterase inhibitory activities of khellactone coumarin derivatives isolated from Peucedanum japonicum Thurnberg.

Authors:  Jeong Hyun Heo; Bo Hyun Eom; Hyung Won Ryu; Myung-Gyun Kang; Jong Eun Park; Doo-Young Kim; Jung-Hee Kim; Daeui Park; Sei-Ryang Oh; Hoon Kim
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

6.  Flavones 7,8-DHF, Quercetin, and Apigenin Against Tau Toxicity via Activation of TRKB Signaling in ΔK280 TauRD-DsRed SH-SY5Y Cells.

Authors:  Ni-Ni Chiang; Te-Hsien Lin; Yu-Shan Teng; Ying-Chieh Sun; Kuo-Hsuan Chang; Chung-Yin Lin; Hsiu Mei Hsieh-Li; Ming-Tsan Su; Chiung-Mei Chen; Guey-Jen Lee-Chen
Journal:  Front Aging Neurosci       Date:  2021-12-15       Impact factor: 5.750

7.  Adlay hull extracts attenuate β-amyloid-induced neurotoxicity and oxidative stress in PC12 cells through antioxidative, anti-inflammatory, and antiapoptotic activities.

Authors:  Gregory J Tsay; Yu-Ta Lin; Chia-Hong Hsu; Feng-Yao Tang; Yueh-Hsiung Kuo; Che-Yi Chao
Journal:  Biochem Biophys Rep       Date:  2021-05-18

8.  Machine learning models to select potential inhibitors of acetylcholinesterase activity from SistematX: a natural products database.

Authors:  Chonny Herrera-Acevedo; Camilo Perdomo-Madrigal; Kenyi Herrera-Acevedo; Ericsson Coy-Barrera; Luciana Scotti; Marcus Tullius Scotti
Journal:  Mol Divers       Date:  2021-06-16       Impact factor: 3.364

Review 9.  Current Knowledge and Perspectives of Pyrrolizidine Alkaloids in Pharmacological Applications: A Mini-Review.

Authors:  Xianqin Wei; Weibin Ruan; Klaas Vrieling
Journal:  Molecules       Date:  2021-03-31       Impact factor: 4.411

10.  Evaluation of cholinesterase inhibitory and antioxidant activity of Wedelia chinensis and isolation of apigenin as an active compound.

Authors:  Md Aminul Islam; Shahed Zaman; Kushal Biswas; Md Yusuf Al-Amin; Md Kamrul Hasan; A H M K Alam; Toshihisa Tanaka; Golam Sadik
Journal:  BMC Complement Med Ther       Date:  2021-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.